Status: Not yet recruiting
Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors
A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.
Participants needed: 420
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd.Updated: Jun 12, 2026
Eligibility criteria
Not listed